The Alliance for Regenerative Medicine (ARM) and UK BioIndustry Association (BIA) release collaborative report offering an in-depth look at ATMP sector trends and metrics in the UK.
The report details industry-specific statistics compiled from 56 cell therapy, gene therapy, tissue engineering, and other ATMP developers headquartered in Europe, including total financings, partnerships and other deals, clinical trial information, and key clinical data events. The Cell and Gene Therapy Catapult provides a high-level overview of the cell and gene therapy ecosystem in the UK, and UK-based companies Autolus Therapeutics, Orchard Therapeutics, Oxford Biomedica, and Synpromics share details on their technology platforms and clinical pipelines.
Key highlights include:
- Financings for ATMP companies grew 66% from £473M to £785M between 2017 and 2018 and stand at £347M for 2019 year to date
- There are 70+ ATMP developers active in the UK, including 56 with UK headquarters
- There are 93 ATMP-specific clinical trials ongoing in the UK, including 27 sponsored by UK-based companies
View Full Report